Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP616803.RAKnLdcBck4RfC0sIBlMSLEBP0GsG4FEabIoWgsKPvD0A130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP616803.RAKnLdcBck4RfC0sIBlMSLEBP0GsG4FEabIoWgsKPvD0A130_assertion type Assertion NP616803.RAKnLdcBck4RfC0sIBlMSLEBP0GsG4FEabIoWgsKPvD0A130_head.
- NP616803.RAKnLdcBck4RfC0sIBlMSLEBP0GsG4FEabIoWgsKPvD0A130_assertion wasGeneratedBy ECO_0000203 NP616803.RAKnLdcBck4RfC0sIBlMSLEBP0GsG4FEabIoWgsKPvD0A130_provenance.
- NP616803.RAKnLdcBck4RfC0sIBlMSLEBP0GsG4FEabIoWgsKPvD0A130_assertion wasDerivedFrom befree-2016 NP616803.RAKnLdcBck4RfC0sIBlMSLEBP0GsG4FEabIoWgsKPvD0A130_provenance.
- NP616803.RAKnLdcBck4RfC0sIBlMSLEBP0GsG4FEabIoWgsKPvD0A130_assertion SIO_000772 17591834 NP616803.RAKnLdcBck4RfC0sIBlMSLEBP0GsG4FEabIoWgsKPvD0A130_provenance.
- NP616803.RAKnLdcBck4RfC0sIBlMSLEBP0GsG4FEabIoWgsKPvD0A130_assertion evidence source_evidence_literature NP616803.RAKnLdcBck4RfC0sIBlMSLEBP0GsG4FEabIoWgsKPvD0A130_provenance.
- NP616803.RAKnLdcBck4RfC0sIBlMSLEBP0GsG4FEabIoWgsKPvD0A130_assertion description "[The standard method for defining prognosis for patients with breast cancer is an integrated model including clinicopathological features, such as tumour size, histological grade, nodal involvement, hormone receptor status and HER-2 overexpression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP616803.RAKnLdcBck4RfC0sIBlMSLEBP0GsG4FEabIoWgsKPvD0A130_provenance.